Immunovant, Inc. – NASDAQ:IMVT

Immunovant stock price today

$14.82
-9.66
-39.49%
Financial Health
0
1
2
3
4
5
6
7
8
9

Immunovant stock price monthly change

-19.89%
month

Immunovant stock price quarterly change

-19.89%
quarter

Immunovant stock price yearly change

-43.78%
year

Immunovant key metrics

Market Cap
3.79B
Enterprise value
1.45B
P/E
-8.72
EV/Sales
N/A
EV/EBITDA
-7.50
Price/Sales
N/A
Price/Book
4.54
PEG ratio
0.50
EPS
-1.74
Revenue
N/A
EBITDA
-233.53M
Income
-223.30M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
0%
Oper. margin
0%
Gross margin
0%
EBIT margin
0%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Immunovant stock price history

Immunovant stock forecast

Immunovant financial statements

Immunovant, Inc. (NASDAQ:IMVT): Profit margin
Dec 2021 0 -41.38M
Mar 2022 0 -47.17M
Mar 2023 0 -59.43M
Mar 2024 0 -75.31M
Immunovant, Inc. (NASDAQ:IMVT): Analyst Estimates
Sep 2025 0 -94.66M
Oct 2025 0 -95.20M
Dec 2025 0 -95.93M
Mar 2026 0 -98.99M
  • Analysts Price target

  • Financials & Ratios estimates

Immunovant, Inc. (NASDAQ:IMVT): Debt to assets
Sep 2022 428146000 32.39M 7.57%
Dec 2022 456243000 41.56M 9.11%
Mar 2023 405838000 43.34M 10.68%
Mar 2024 666712000 48.95M 7.34%
Immunovant, Inc. (NASDAQ:IMVT): Cash Flow
Dec 2021 -31.89M -74K 0
Mar 2022 -32.95M -118K 0
Mar 2023 -55.79M -26K 233K
Mar 2024 -59.69M -150K 1.54M

Immunovant alternative data

Immunovant, Inc. (NASDAQ:IMVT): Employee count
Sep 2023 164
Oct 2023 164
Nov 2023 164
Dec 2023 164
Jan 2024 164
Feb 2024 164
Mar 2024 164
Apr 2024 164
May 2024 164
Jun 2024 164
Jul 2024 207

Immunovant other data

12.77% -35.66%
of IMVT is owned by hedge funds
16.41M -40.03M
shares is hold by hedge funds

Immunovant, Inc. (NASDAQ:IMVT): Insider trades (number of shares)
Period Buy Sel
Jan 2024 0 22188
Feb 2024 0 22885
Apr 2024 0 98566
May 2024 0 29941
Jul 2024 0 41401
Aug 2024 0 28185
Oct 2024 0 38326
Nov 2024 0 27869
Dec 2024 0 13175
Transaction Date Insider Security Shares Price per share Total value Source
Sale
PANDE ATUL director
Common Stock 7,750 $28.54 $221,185
Sale
HUGHES DOUGLAS J. director
Common Stock 5,425 $28.54 $154,830
Sale
LEVINE MARK S. officer: Chief Legal Officer
Common Stock 3,650 $25.45 $92,893
Sale
MACIAS WILLIAM L. officer: Chief Medical Officer
Common Stock 3,353 $25.45 $85,334
Sale
BARNETT EVA RENEE officer: Chief Financial Officer
Common Stock 4,174 $25.45 $106,228
Sale
SALZMANN PETER director, officer: Chief Execut..
Common Stock 16,692 $25.45 $424,811
Sale
LEVINE MARK S. officer: Chief Legal Officer
Common Stock 4,361 $29.53 $128,780
Sale
GEFFNER MICHAEL officer: Chief Medical Officer
Common Stock 3,189 $29.53 $94,171
Sale
STOUT JAY S officer: Chief Technology Officer
Common Stock 2,740 $29.53 $80,912
Sale
SALZMANN PETER director, officer: Chief Execut..
Common Stock 9,095 $28.79 $261,845
Insider Compensation
Dr. Peter Salzmann M.B.A., M.D. (1968) Chief Executive Officer & Director
$1,020,000
Dr. Julia G. Butchko Ph.D. (1971) Chief Devel. & Technology Officer $531,000
Dr. Frank M. Torti M.B.A., M.D., MBA (1979) Executive Chairperson of the Board
$97,500
Friday, 27 December 2024
seekingalpha.com
Wednesday, 11 December 2024
globenewswire.com
Friday, 8 November 2024
zacks.com
Thursday, 7 November 2024
globenewswire.com
Tuesday, 29 October 2024
globenewswire.com
Monday, 9 September 2024
benzinga.com
zacks.com
benzinga.com
globenewswire.com
globenewswire.com
Thursday, 5 September 2024
zacks.com
Tuesday, 6 August 2024
seekingalpha.com
Thursday, 30 May 2024
zacks.com
Wednesday, 29 May 2024
globenewswire.com
investors.com
Monday, 13 May 2024
Zacks Investment Research
Monday, 6 May 2024
Zacks Investment Research
Monday, 22 April 2024
Zacks Investment Research
Wednesday, 17 April 2024
Zacks Investment Research
Thursday, 4 April 2024
Seeking Alpha
Monday, 25 March 2024
InvestorPlace
Thursday, 21 March 2024
Investors Business Daily
Wednesday, 13 March 2024
Zacks Investment Research
Friday, 8 March 2024
Zacks Investment Research
Tuesday, 13 February 2024
Zacks Investment Research
Tuesday, 6 February 2024
InvestorPlace
Friday, 19 January 2024
InvestorPlace
Tuesday, 9 January 2024
Seeking Alpha
Thursday, 21 December 2023
Zacks Investment Research
Investors Business Daily
  • What's the price of Immunovant stock today?

    One share of Immunovant stock can currently be purchased for approximately $14.82.

  • When is Immunovant's next earnings date?

    Unfortunately, Immunovant's (IMVT) next earnings date is currently unknown.

  • Does Immunovant pay dividends?

    No, Immunovant does not pay dividends.

  • How much money does Immunovant make?

    Immunovant has a market capitalization of 3.79B.

  • What is Immunovant's stock symbol?

    Immunovant, Inc. is traded on the NASDAQ under the ticker symbol "IMVT".

  • What is Immunovant's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Immunovant?

    Shares of Immunovant can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Immunovant's key executives?

    Immunovant's management team includes the following people:

    • Dr. Peter Salzmann M.B.A., M.D. Chief Executive Officer & Director(age: 57, pay: $1,020,000)
    • Dr. Julia G. Butchko Ph.D. Chief Devel. & Technology Officer(age: 54, pay: $531,000)
    • Dr. Frank M. Torti M.B.A., M.D., MBA Executive Chairperson of the Board(age: 46, pay: $97,500)
  • How many employees does Immunovant have?

    As Jul 2024, Immunovant employs 207 workers, which is 26% more then previous month and 26% more then previous quarter.

  • When Immunovant went public?

    Immunovant, Inc. is publicly traded company for more then 6 years since IPO on 21 Jun 2019.

  • What is Immunovant's official website?

    The official website for Immunovant is immunovant.com.

  • Where are Immunovant's headquarters?

    Immunovant is headquartered at 320 West 37th Street, New York, NY.

  • How can i contact Immunovant?

    Immunovant's mailing address is 320 West 37th Street, New York, NY and company can be reached via phone at +91 75803099.

Immunovant company profile:

Immunovant, Inc.

immunovant.com
Exchange:

NASDAQ

Full time employees:

207

Industry:

Biotechnology

Sector:

Healthcare

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

320 West 37th Street
New York, NY 10018

CIK: 0001764013
ISIN: US45258J1025
CUSIP: 45258J102